Table 2.

Summary of treatment‐emergent adverse events observed in at least 5% of patients in any treatment group

	OPA‐15406 0.3%, n = 24	OPA‐15406 1%, n = 25	Vehicle, n = 24
Infections and infestations, n (%)
Influenza	2 (8.3)	1 (4.0)	0 (0.0)
Viral upper respiratory tract infection	1 (4.2)	0 (0.0)	2 (8.3)
Investigations, n (%)
Blood alkaline phosphatase increased	0 (0.0)	2 (8.0)	0 (0.0)
Respiratory, thoracic and mediastinal disorders, n (%)
Upper respiratory tract inflammation	1 (4.2)	6 (24.0)	2 (8.3)
Skin and subcutaneous tissue disorders, n (%)
Dermatitis atopic	2 (8.3)	1 (4.0)	4 (16.7)

Treatment‐emergent adverse events were coded to preferred terms according to the Medical Dictionary for Regulatory Activities (MedDRA)/J version 20.0.